# Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

> **NCT04877691** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 367 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Medi-546
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04877691
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-08
- **Primary completion:** 2025-08-22
- **Final completion:** 2026-11-06
- **Target enrollment:** 367 (ACTUAL)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04877691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04877691, "Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04877691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*